Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

Completed · Phase 1

Conditions studied: Neoplasms

In brief

The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).

Key facts

Study ID

NCT00207077

Run by

Eli Lilly and Company

People needed

33

Starts

2005-08-01

Expected to finish

2007-05-01

Last updated by the study team

2015-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Measurable disease
• Life expectancy of at least 3 months
• Must have at least one prior chemotherapy containing a platinum

You may not qualify if…

• Known or documented brain metastases
• Prior cetuximab therapy

Where it is running

• Christiana Care Health Services, Inc. — Newark, Delaware, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.